Ignite Creation Date:
2024-05-05 @ 12:04 PM
Last Modification Date:
2024-10-26 @ 9:20 AM
Study NCT ID:
NCT00234481
Status:
TERMINATED
Last Update Posted:
2008-06-04
First Post:
2005-10-05
Brief Title:
Safety Study of XL844 in Subjects With Chronic Lymphocytic Leukemia
Sponsor:
Exelixis
Organization:
Exelixis
Study Overview
Official Title:
A Phase 1 Dose-Escalation Study of the Safety Pharmacokinetics and Pharmacodynamics of XL844 Administered Orally to Subjects With Chronic Lymphocytic Leukemia
Status:
TERMINATED
Status Verified Date:
2008-06
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Study closed due to slow enrollment
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to assess the safety and tolerability of different doses of XL844 when given orally to adults with recurrent or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None